Diffuse Large B Cell Lymphoma  >>  dexamethasone  >>  Phase 2
Welcome,         Profile    Billing    Logout  

15 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
dexamethasone / Generic mfg.
NCT00556127: Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell Lymphoma

Completed
2
94
Europe
Rituximab, Epirubicin, Cyclophosphamide, Vincristine, Prednisone, Granulocyte-colony-stimulating factor, Mitoxantrone, Cytarabine ARA-C, Dexamethasone, Carmustine BCNU, Etoposide, Melphalan, Radiotherapy, PBSC reinfusion
Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie
Diffuse Large B-Cell Lymphoma, POOR PROGNOSIS
 
09/06
NCT00823719: Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Checkmark
May 2013 - May 2013: 
Checkmark P2 data
Nov 2011 - Nov 2011: P2 data
Completed
2
61
US
ofatumumab + ICE, ofatumumab + DHAP
GlaxoSmithKline
Lymphoma, Large-Cell, Diffuse
07/11
09/11
NCT00836173: Rituximab, Ifosfamide, Carboplatin, and Etoposide (RICE) Followed by Gallium Nitrate, Rituximab and Dexamethasone (GARD) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Withdrawn
2
0
US
RICE, GaRD Treatment
Loyola University, Genta Incorporated
Diffuse Large B-cell Lymphoma
05/12
05/12
2014-001620-29: Clinical trial to evaluate the treatment with a drug (lenalidomide) with the usually prescribed chemotherapy in patients diagnosed with diffuse large B-cell lymphoma (sort of blood cancer) which did not respond to previous treatments and who can not receive high-dose chemotherapy. Ensayo clínico para evaluar el tratamiento con un medicamento (lenalidomida) añadido a la quimioterapia utilizada habitualmente en pacientes con linfoma difuso de células grandes B (cáncer de la sangre) que no han respondido bien a tratamientos previos y que no pueden recibir quimioterapia a altas dosis

Ongoing
2
77
Europe
Lenalidomide, Rituximab, Gemcitabine, Cisplatin, NA, Capsule, hard, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Revlimid 5 mg, MabThera, Revlimid 10 mg, Revlimid 15 mg
Grupo Español para el Tratamiento y Estudio de los Linfomas (GOTEL), Grupo Español para el Tratamiento y Estudio de los Linfomas (GOTEL)
Refractory Diffuse large B-cell lymphoma. Linfoma difuso de células grandes B refractarios., Sort of cancer (Large B cells lymphoma) from specific haematological cells (from the blood). Tipo de cáncer (Linfoma de cálulas B grandes) que afecta a determinadas células hematológicas (de la sangre), Diseases [C] - Cancer [C04]
 
 
NCT02420210: Bendamustine, Obinutuzumab, and Dexamethasone in Older Patients With Diffuse Large B-cell Lymphoma

Terminated
2
2
US
Bendamustine Hydrochloride, Ribomustin, SyB L-0501, Treanda, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA101, Gazyva, R7159, RO 5072759, Dexamethasone, DM, Quality-of-Life Assessment, Quality of Life Assessment, Laboratory Biomarker Analysis
University of Chicago, National Cancer Institute (NCI)
Diffuse Large B-Cell Lymphoma
08/16
08/16
STORM, NCT01653067 / 2011-001491-20: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma

Unknown status
2
88
Europe
Rituximab, Temsirolimus, DHAP, intravenous, Temsirolimus-R-DHAP, Torisel, MabThera, Fortecortin, ARA-C, ARA-cell, Depocyte, R-DHAP, Rituximab-DHAP, Temsirolimus,Rituximab,Dexamethasone,Cisplatine,Cytarabine, Temsirolimus-Rituximab-DHAP
Mathias Witzens-Harig, Johannes Gutenberg University Mainz, Technische Universität München, Ludwig-Maximilians - University of Munich, University Hospital Ulm, University Hospital Erlangen, Charite University, Berlin, Germany, University Hospital Freiburg, Johann Wolfgang Goethe University Hospital
Diffuse Large B-Cell Lymphoma
06/18
07/18
IBDCL-GELTAMO-2015, NCT02692248 / 2015-005390-21: Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to Autologous Stem Cell Transplantation

Unknown status
2
62
Europe
Ibrutinib, Rituximab, Gemcitabine, Oxaliplatin, Dexamethasone
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea, Janssen-Cilag, S.A.
Diffuse Large B-Cell Lymphoma
09/20
09/20
NCT02955823: A Phase II Study of the FIL on Elderly Frail Patients With DLBCL

Completed
2
68
Europe
Rituximab-Dexamethasone-Lenalidomide
Fondazione Italiana Linfomi ONLUS
Diffuse Large B-cells Non-Hodgkin Lymphoma
09/20
11/22
NCT05852717: Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma

Recruiting
2
32
US
AutoSCT OR CAR T-cell Therapy, Autologous transplant, chimeric antigen receptor (CAR) T-cell, GDP, Epcoritamab
Dipenkumar Modi, Genmab
Large Cell Lymphoma, Diffuse, Relapsed Cancer, Refractory Cancer
06/24
06/25
NCT05498220: Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2
44
US
Polatuzumab vedotin (PV), Rituximab, Hyaluronidase, Gemcitabine, Cisplatin, Dexamethasone, GCSF
UNC Lineberger Comprehensive Cancer Center, Genentech, Inc.
Diffuse Large B-cell Lymphoma
08/28
08/28
ARIA, NCT05205252: A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.

Calendar Jan 2023 - Dec 2024: Data from trial for hematological malignancies
Withdrawn
1b/2
156
US
Tazemetostat, IPN60200, Tafasitamab, Lenalidomide, Acalabrutinib, Bruton tyrosine kinase inhibitor, Daratumumab (Intravenously), Mosunetuzumab, Daratumumab (Subcutaneously), Hyaluronidase-Fihj, Pomalidomide, Dexamethasone 20mg
Epizyme, Inc.
Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy
07/23
07/23
NCT04882163: Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma

Withdrawn
1b/2
0
Europe, US, RoW
CC-220, Iberdomide, Polatuzumab vedotin, Rituximab, Tafasitamab, Gemcitabine, Cisplatin, Dexamethasone, Bendamustine, Lenalidomide
Celgene
Lymphoma, B-Cell
04/26
04/29
NCT02983097 / 2009-010824-25: Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP

Terminated
1/2
34
Europe
Rituximab, MabThera, Cisplatin, Cisplatinum, Carboplatin, Carboplatinum, Dexamethasone, Cytarabine, Cytarabin, Ara-C, Lenalidomide, Revlimid, PegFilgrastim, Neulasta, peripheral stem cell collection, peripheral stem cell apheresis, hematopoetic stem cell apheresis, peripheral hematopoetic stem cell apheresis
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH, Celgene, Amgen
Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma Grade III (FL III°), Mantle Cell Lymphoma (MCL), Blastoid Variant, Burkitt Lymphoma (BL), Aggressive Marginal Zone Lymphoma (MZL)
01/14
04/15
ZUMA-1, NCT02348216 / 2015-005007-86: Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma

Checkmark Data from ZUMA-1 trial for R/R LBCL at ASH 2022
Dec 2022 - Dec 2022: Data from ZUMA-1 trial for R/R LBCL at ASH 2022
Checkmark Presentation from ZUMA-1 trial for DLBCL at ASTCT 2021
Feb 2021 - Feb 2021: Presentation from ZUMA-1 trial for DLBCL at ASTCT 2021
Checkmark Presentation from ZUMA-1 trial for DLBCL at ASH 2020
More
Completed
1/2
307
Europe, Canada, US, RoW
Axicabtagene Ciloleucel, Yescarta®, Fludarabine, Cyclophosphamide, Levetiracetam, Tocilizumab, Dexamethasone, High-dose methylprednisolone, Bendamustine, Rituximab, Doxorubicin, Prednisone, Vincristine, Ifosfamide, Carboplatin, Etoposide, Gemcitabine, Oxaliplatin, Cisplatin, Methylprednisolone
Kite, A Gilead Company
Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL), Primary Mediastinal B-cell Lymphoma (PMBCL), High Grade B-cell Lymphoma (HGBCL)
07/23
07/23
EPCORE NHL-2, NCT04663347 / 2020-000845-15: Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)

Checkmark Data from arm 6 of EPCORE NHL-2 trial for r/r/ follicular lymphoma at ASH 2022
Dec 2022 - Dec 2022: Data from arm 6 of EPCORE NHL-2 trial for r/r/ follicular lymphoma at ASH 2022
Checkmark Data from arm 2b of EPCORE NHL-2 trial for r/r follicular lymphoma at ASH 2022
Dec 2022 - Dec 2022: Data from arm 2b of EPCORE NHL-2 trial for r/r follicular lymphoma at ASH 2022
Checkmark Data from arm-4 of EPCORE NHL-2 trial for r/r DLBCL at ASH 2022
More
Recruiting
1/2
662
Europe, US, RoW
rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, R-CHOP, rituximab and lenalidomide, R2, rituximab and bendamustine, BR, rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin, R-DHAX/C, gemcitabine and oxaliplatin, GemOx, Epcoritamab, GEN3013, DuoBody®-CD3xCD20, EPKINLY™, rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone, R mini-CHOP, Lenalidomide, rituximab, ifosfamide, carboplatin, and etoposide phosphate, R-ICE
Genmab, AbbVie
Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
03/29
03/29

Download Options